A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

计划入组 120 人 · 首次发布于 2012 年 10 月 26 日

Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

计划入组 12 人 · 首次发布于 2019 年 11 月 25 日

First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10

计划入组 20 人 · 首次发布于 2011 年 11 月 10 日

Water-soluble FZD–LRP5/LRP6 heterodimerizers

Ipafricept

Vantictumab

LIFEPharma FZE

United Arab Emirates

FSD Pharma, Inc.

Canada

ZYDUS LIFESCIENCES GLOBAL FZE

United Arab Emirates

Surrozen Secures Key Patent for Antibody-Based Wnt Pathway Modulators with Potential in Retinal Disease Treatment

āshibio Licenses Vantictumab for Rare Bone Disease ADO2 in Strategic Pipeline Expansion

Novel Frizzled 7 Antibody Shows Promise Against Wilms Tumor Through Wnt Pathway Disruption